Introduction
Mitral regurgitation (MR) is a valvular heart disease that is associated with significant morbidity and mortality. 1 Ten percent of persons aged over 75 have moderate or severe MR and 50% of patients with clinically significant MR are denied surgery due to risks associated with open heart surgery. 2, 3 When left untreated severe MR carries a 1-year mortality of up to 57%. 4 Transcatheter mitral valve intervention (TMVI) repairs or replaces the mitral valve through small arterial and venous entry sites and so avoids risks associated with open heart surgery. TMVI can be offered to patients who are unable to tolerate open heart surgery. Several transcatheter devices are currently being developed worldwide. This article will discuss the basic science of MR and devices under trial in Australia for TMVI.
Anatomy
The mitral valve apparatus is comprised of an annulus, leaflets, chordae and papillary muscles (Fig. 1) . The annulus is a D-shaped ring made of non-conductive fibrofatty tissue. The straight border abuts the aortic valve and forms a fibrous continuity known as the aorto-mitral curtain. The fibrous tissue expands at either edge of the curtain to form the left and right fibrous trigone. 5, 6 The anterior leaflet forms one third of the annular circumference while the posterior leaflet comprises two third of the annular circumference. The two leaflets form a single continuous structure with the edge of the closure line referred to as the anterolateral and posteromedial commissures. The free edge of the leaflets is divided into lateral, middle and medial scallops termed A1, A2, A3 and P1, P2, P3 respectively. 5, 7 The larger posteromedial muscle is typically supplied by a single dominant right coronary, and hence is more prone to infarction and rupture causing acute MR as compared to the smaller anterolateral muscle which typically has dual supply from the left anterior descending and left circumflex artery. 8 
Pathophysiology
MR is caused by change in the structure or function of the leaflets, annulus or left ventricle. Chronic severe MR almost always involves change in the structure of all three components; however, the relative importance of each in the formation of MR is unknown. Biomechanical studies have proven that change in geometry of any of the three components leads to altered annular tension, resulting in annular dilatation and increased MR. [9] [10] [11] [12] MR can be classified into degenerative MR (DMR) or functional MR (FMR). DMR is due to structural or degenerative abnormalities in the mitral valve apparatus (annulus, leaflets, chordae tendinae or papillary muscles). As DMR progresses, the pathology extends to the entire apparatus deforming the left ventricle, annulus, chords and papillary muscles. 13 The prevalence of degenerative MR with mitral valve prolapse is around 2% and of this cohort 4% having severe MR.
14 FMR occurs from a change in the mitral valve geometry secondary to ischaemic or non-ischaemic left ventricular dysfunction and in the absence of organic mitral valve disease. 15 The two processes can coexist in the one patient and mixed forms of the disease are not uncommon. MR has been detected on transthoracic echocardiography in 50% of patients after myocardial infarction with 12% having severe MR. 16 In a study of 470 patients with idiopathic dilated cardiomyopathy, 38% had moderate or severe MR 17 The most common finding in DMR is mitral valve prolapse which encompasses a spectrum of connective tissue disorders including fibroelastic deficiency and Barlow disease. Fibroelastic deficiency occurs in patients typically over the age of 60 and has a relatively short clinical history. The pathophysiology is characterised by impaired production of connective tissue leading to rupture of one or more chordae but most commonly the middle scallop of the posterior leaflet (Fig. 1) . The affected leaflet may either appear normal or develop myxomatous changes with mucopolysaccharide accumulation. 18 In contrast, Barlow disease is characterised by diffuse excessive myxoid tissue in multiple redundant leaflet segments along with chordal elongation and rupture and mitral annular dilatation (Fig. 1) . Patients typically present under the age of 60 and have a longer history of MR. 18, 19 In FMR, left ventricular pathology results in a secondary effect on the function of the mitral valve apparatus by causing papillary muscle displacement, leaflet tethering, annular flattening and enlargement. 13 In ischaemic FMR, the consequence of left ventricular scar and remodelling results in focal systolic tenting of the mitral valve with resultant MR in the presence of overall preserved left ventricular ejection fraction. Mitral annular dilatation occurs late in the pathophysiology and typically involves the posterior annulus. 20 Non-ischaemic FMR, usually due to cardiomyopathy, is characterised by spherical left ventricular dilatation with concurrent symmetric mitral annular dilatation which reduces leaflet coaptation resulting in a posterior or centrally directed regurgitant jets. 21 Acute MR may be due to infection causing leaflet perforation or spontaneous chordal rupture in degenerative valve disease.
History, examination and diagnosis
Patients with chronic MR typically present with progressive dyspnoea over months to years. On clinical examination, there is a diminished S1, wide splitting of S2 and a holosystolic murmur best heard at the apex. In patients with mitral valve prolapse a mid-systolic click followed by a late systolic murmur is heard. Echocardiography is the cornerstone of the diagnostic evaluation of MR with qualitative and quantitative measures used to establish severity. Patients with a central jet >40% of the left atrium, vena contracta ≥0.7 cm, regurgitant volume ≥ 60 mL, regurgitant fraction ≥50% or effective regurgitant orifice ≥0.40cm
2 are considered to have severe organic MR. In functional ischaemic MR, an EROA ≥20 mm2 or an R Vol ≥ 30 mL identifies a subset of patients at increased risk of cardiovascular events. Both the pulsed Doppler mitral to aortic TVI ratio and the systolic pulmonary flow reversal are specific for severe MR 22 ( Fig. 2) . Patients suffering acute MR typically present with overt heart failure and cardiogenic shock due to acute volume overload in the left ventricle and require emergent intervention. 23 Prognosis and treatment MR begets MR. In both aetiologies, MR causes left ventricular volume overload resulting in chamber and annular dilation thus increasing the severity of MR and worsening left ventricular size and function. 24 Patients with severe DMR may remain asymptomatic for years and only develop symptoms once LV systolic dysfunction occurs. In contrast FMR, where there is underlying LV dysfunction, often presents earlier with symptoms of congestive heart failure. 14 Mitral valve surgery is recommended in patients with severe DMR and symptoms or without symptoms but evidence left ventricular dysfunction (left ventricular ejection fraction 30% to 60% or LV end systolic diameter > 40 mm). Mitral valve repair is preferred to replacement when surgically suitable. Symptomatic patients with chronic DMR, left ventricular ejection fraction <60% and who are not operable candidates should receive guideline directed medical therapy for left ventricular dysfunction, including angiotensin-converting enzyme inhibitors, β-blockers and aldosterone antagonists; however, there is little evidence demonstrating significant benefit of medical therapy in severe MR. 23 In FMR, there are limited data to show that MR correction improves morbidity or mortality and as such only a Class IIb indication exists for surgical correction of secondary MR in severely symptomatic patients with persistent symptoms despite optimal medical therapy. 23 All patients with functional MR and reduced left ventricular ejection fraction should receive guideline directed medical therapy for left ventricular dysfunction. Surgery is currently the gold standard treatment for MR. Correction of severe FMR at the time of concomitant surgery, for instance coronary bypass surgery, is often considered as standard care. 25 Mitral valve repair is recommended in preference to replacement when surgical treatment is indicated and a durable repair can be accomplished. If the mitral valve has to be replaced bioprosthetic valve replacement is associated with low embolic risk but shorter durability whereas mechanical valve replacement has longer lasting durability but is associated with high risk of embolism necessitating lifelong anticoagulation. 23 Unfortunately, a significant proportion of patients who need surgery are not operative candidates and up to 50% of patients with severe MR not being referred for surgery. 3, 13 Furthermore, mitral valve surgery can be associated with significant morbidity and mortality with one study of octogenarians reporting a mortality and morbidity rate of 17 and 35.5% respectively following mitral valve surgery. 1, 26 This has led to the development of TMVI as a treatment option for patients who are not surgical candidates. (Fig. 3) . The procedure involves placing the patient under general anaesthesia and the femoral vein is accessed via needle puncture and a delivery system inserted. A catheter is then advanced to the right atrium and under fluoroscopic and transoesophageal echocardiography guidance a transeptal puncture into the left atrium is performed. The trans-septal sheath is exchanged for a steerable guide catheter and dilator. The clip delivery system is introduced into the guide catheter and the MitraClip device advanced into the left atrium. The clip is centred over the origin of the regurgitant jet and advanced into the left ventricle. Leaflets are grasped by clip arms and trapped between grippers and clip when the device is closed. Leaflet position and residual regurgitation is assessed at the time and if needed the clip can be re-opened and repositioned. 27 If there is significant residual MR, often a second or even third device can be implanted. The MitraClip procedure is generally well tolerated even in patients with severe left ventricular dysfunction as compared to other types of TMVr.
Percutaneous valve intervention
Initial trials established the safety and feasibility of mitral valve repair using the MitraClip system in patients at high surgical risk with improvements in dyspnoea and low rates of procedure related adverse event and mortality. 28, 29 In the EVEREST (Endovascular Valve Edge-toEdge Repair Study) II clinical trial a comparison was made to conventional surgery. Five-year data revealed the MitraClip system had higher rates of significant residual MR (12.3% vs 1.8%; P = 0.02) and reoperation rates within the first 6 months (27.9% vs 8.9%; P = 0.003). There was no difference in survival between the two treatment strategies. 30 The MitraClip system was approved by the US Food and Drug Administration in 2013 for patients with significant severe DMR who are at prohibitive risk for MV surgery.
Edwards PASCAL mitral valve repair system
The Edwards PASCAL system (Edwards Lifesciences, CA, USA) is a new TMVr system which employs mitral leaflet grasping to reduce MR. The system offers the following potential advantages; large implant size with spacer, long paddles facilitating grasping of the valve leaflets, independent leaflet clasping and minimal dependence on septal puncture height. Initial results in human trials have demonstrated percutaneous mitral repair with the Edwards PASCAL™ system appears safe and feasible. A prospective multicentre study has been intitiated that will assess a composite end-point of all-cause mortality or recurrent heart failure hospitalisations and has an estimated primary completion date in July 2018.
31,32

Cardioband annuloplasty
The Cardioband device (Valtech Cardio, OrYehuda, Israel) involves a percutaneous direct annuloplasty that does not use the coronary sinus. The femoral vein is accessed and a catheter advanced into the right atrium. A transeptal puncture is performed through which the delivery system enters the left atrium. The device is then delivered around the mitral annulus, secured in place through locking screws and tightened, thereby reducing the mitral annular circumference (Fig. 4) . A multicentre feasibility study of the Cardioband device was conducted in 31 patients with functional MR. The Cardioband device was implanted percutaneously via the trans-septal approach under fluoroscopic and transoesophageal echocardiography guidance. It was successfully implanted in 29 patients, with no severe MR at the end of the procedure and 82% had <2+ MR at 30 days. There were 16 serious adverse events that occurred in nine patients including stroke, pericardial effusion, open heart surgery and renal insufficiency. The study demonstrated the feasibility and safety of percutaneous direct mitral annuloplasty with the Cardioband device in high-risk patients with MR. 25, 33 Carillon mitral contour system
The Carillon device (Cardiac Dimension, WA, USA) is a metal rod with hoop-shaped helical anchors at either end (Fig. 5) . Patients are sedated or anaesthetised for the procedure and the coronary sinus is cannulated from the jugular vein with a 9Fr delivery catheter. The distal anchor is deployed in the great cardiac vein and traction placed to plicate the mitral annulus and the proximal anchor then deployed. The degree of traction is assessed in the procedure using echocardiographic assessment and coronary angiography performed to ensure patency of the left circumflex artery that runs in close proximity to the great cardiac vein. Percutaneous mitral annuloplasty using the Carillon device was evaluated for safety and efficacy in a prospective, non-randomised, nonblinded trial in patients with symptomatic severe FMR. Of the 53 patients who were fully qualified, 36 underwent permanent device implantation, 17 had the device recaptured wither due to coronary artery compromise or failure to improve MR. At 12 months, MR and left ventricular volumes were significantly lower in the treatment group and exercise tolerance assessed with 6-min walk test was markedly improved in the implant patients. 34 
Tendyne valve
The Tendyne valve (Tendyne Incorporated, MN, USA) is a trileaflet pericardial valve sewn onto a self-expanding nitinol frame with an atrial and ventricular fixation system tethered to the left ventricular apex. The procedure involves placing the patient under general anaesthesia and a left minithoracotomy is performed to gain access to the LV apex. A guidewire, dilator and sheath are inserted sequentially through the LV apex to gain access to the left atrium. The valve is then advanced through the sheath and deployed in the left atrium. A polymer tether attached to the ventricular end of the device is then attached to the outer surface of the LV apex and used to position the valve in the native annulus and hold it in place (Fig. 6) .
The first in-human transcatheter mitral valve replacement (TMVR) with the Tendyne valve was performed on two patients with severe degenerative MR in 2013. Immediately after deployment, MR, left atrial pressure and pulmonary capillary wedge pressure were all significantly reduced. Both patients underwent subsequent mitral valve replacement surgery as per the study protocol and both Tendyne valves were explanted without any damage to the mitral valve, annulus or subvalvular structures. 35 The Tendyne Early Feasibility trial recruited 30 patients with symptomatic MR (DMR or FMR) in a prospective, open-label, non-randomised trial to establish the safety and efficacy of the Tendyne mitral valve prosthesis. The primary end-points were MR grade < 2 at 90 days and freedom from cardiovascular death, stroke, myocardial infarction or surgery for valve related dysfunction. 36 Successful device implantation was achieved in 28 patients (93.3%) with no acute death, stroke or myocardial infarction. Left ventricular volume had improved at 30 days and 75% of patients reported no symptoms at follow-up. In this small study the Tendyne mitral valve prosthesis appears to be a safe and effective therapy for patients with MR of either aetiology. 36 
Twelve Transcatheter mitral valve
The Twelve transcatheter mitral valve (Twelve Inc., CA, USA) is TMVR device being evaluated in a prospective, multicentre, non-randomised pilot study to establish safety and efficacy in patients with severe symptomatic MR who are not surgical candidates. 37 It is composed of a self-expanding nitinol frame with a trileaflet valve composed of bovine pericardium. It has a fabric sealing skirt and requires transapical delivery. The primary outcome evaluated will be major adverse events at 30-days and secondary outcomes will be procedural success and MR reduction.
Valve-in-valve TMVR for degenerated bioprosthetic valves
Bioprosthetic mitral valves eventually degenerate and can require correction. Mitral valve reoperations are associated with higher mortality due to patient and procedure related factors. 38 Valve-in-valve TMVR can spare patients the need for complex reoperation and experience in this technique is continuing to grow.
The advantage of bioprosthetic valve is the rigid structure with a fixed circumference making it an ideal target for TMVR. The TMVR size is easy to determine and cylindrical devices used for transcathter aortic valve implantation can be used. Studies have demonstrated acceptable results in valve-in-valve TMVR with successful implantation, correction of mitral bioprosthetic valvulopathy and minimal postoperative complications. [39] [40] [41] Traditionally, a transapical access was required but the majority of cases can now be undertaken through a transeptal puncture thus expediting patient recovery. Tendyne device with tether and apical button (B). Balloon tipped catheter advanced through the mitral valve into the left atrium (C). Tendyne valve delivered into the mitral valve annulus through delivery sheath (D). Delivery sheath removed and apical tether pulled towards left ventricular apex (E). Tether fixed in position using button attached externally to the left ventricular apex (F). Tendyne valve post implantation. 45 
Unresolved issues in TMVI
Several concurrent unresolved technical issues exist which limit the clinical utility of TMVI. Potential limitations of percutaneous annuloplasty are that the coronary sinus only allows reduction of part of the annulus, technically stabilisation of material with enough force to obtain more than 20% diameter reduction is a challenge and proximity to the left circumflex artery with potential artery compression and ischaemia means non coronary sinus approaches are being investigated. 13 Patients with long-standing MR often have a dilated annulus necessitating large delivery systems to deploy them. In some cases, the patient's mitral apparatus cannot suitably accommodate the percutaneous valve, in particular, bulky TMVR devices are also prone to causing LVOT obstruction and CT planning is necessary to predict and prevent this occurring. TMVr does not completely eliminate MR and the degree of MR reduction required to obtain clinical benefit is unknown. Indeed assessment of the severity of MR after intervention is difficult due to multiple eccentric jets and artefact from the clips. 42 TMVI is one of the more challenging cardiac interventions, and requires advanced imaging only available in a few centres and a longer learning curve which may limit its uptake. 42 A plethora of devices exist aimed at percutaneously correcting MR and are currently under investigation. Results from initial animal and first-in-human studies are encouraging and it is likely that options will continue to grow and designs refined to improve outcome. 35, 42 Conclusion MR is a valvular heart disease that is associated with significant morbidity and mortality. The mitral valve apparatus consists of an annulus, leaflets and left ventricular attachments all of which contribute to mitral regurgitation. TMVI either through TMVr or TMVR is an emerging treatment modality for MR. Devices targeting components of the mitral apparatus are being developed in response to the burgeoning demand for this minimally invasive therapy. Numerous challenges remain including developing more adaptable devices and correction of multiple components of the mitral apparatus to attain durable results. There will likely be a complementary role between surgery and TMVI in the near future.
